GT Biopharma (GTBP) Net Equity Issued and Repurchased (2021 - 2026)

GT Biopharma (GTBP) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 549.84% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $13.9 million (up 2155.68% YoY), while the FY2025 annual figure was $10.5 million, up 253.09% from the prior year.
• Net Equity Issued and Repurchased steadied at $4.0 million in Q1 2026 per GTBP's latest filing, from $4.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $6.3 million in Q1 2023 and bottomed at $616000.0 in Q1 2025.
• Historically, Net Equity Issued and Repurchased has averaged $3.5 million across 3 years, with a median of $4.0 million in 2025.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 549.84% in 2026 and fell as far as 549.84% in 2026.
• GT Biopharma's Net Equity Issued and Repurchased stood at $6.3 million in 2023, then tumbled by 36.1% to $4.0 million in 2025, then slipped by 0.05% to $4.0 million in 2026.
• Business Quant data shows GTBP's Net Equity Issued and Repurchased at $4.0 million in Q1 2026, $4.0 million in Q4 2025, and $1.1 million in Q3 2025.